160 related articles for article (PubMed ID: 36877373)
1. Myeloid sarcoma: current approach and therapeutic options.
Avni B; Koren-Michowitz M
Ther Adv Hematol; 2011 Oct; 2(5):309-16. PubMed ID: 23556098
[TBL] [Abstract][Full Text] [Related]
2. Retracted: Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia.
Methods In Medicine CAM
Comput Math Methods Med; 2023; 2023():9837485. PubMed ID: 37829540
[TBL] [Abstract][Full Text] [Related]
3. Secondary myeloid sarcoma in the prostate: A case report.
Luo C; Liu L; Zhang G
Asian J Surg; 2024 Mar; 47(3):1636-1638. PubMed ID: 38161133
[No Abstract] [Full Text] [Related]
4. Primary myeloid sarcoma in an infant with an NRAS mutation.
Kamat A; Opipari V; Habiger C; Jasty R; Mody R; Sedig L
Pediatr Blood Cancer; 2024 Jun; 71(6):e30946. PubMed ID: 38462746
[No Abstract] [Full Text] [Related]
5. Current Challenges in the Characterization of Myeloid Neoplasms.
Geyer JT
Pathobiology; 2024; 91(1):5-7. PubMed ID: 38142689
[No Abstract] [Full Text] [Related]
6. Myeloid sarcoma: An overview.
Ramia de Cap M; Chen W
Semin Diagn Pathol; 2023 May; 40(3):129-139. PubMed ID: 37149396
[TBL] [Abstract][Full Text] [Related]
7. Myeloid sarcoma: more and less than a distinct entity.
Loscocco GG; Vannucchi AM
Ann Hematol; 2023 Aug; 102(8):1973-1984. PubMed ID: 37286874
[TBL] [Abstract][Full Text] [Related]
8. "Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect.
An Y; Jin X; Zhang H; Zhang M; Mahara S; Lu W; Zhao M
Curr Treat Options Oncol; 2023 May; 24(5):409-441. PubMed ID: 37010679
[TBL] [Abstract][Full Text] [Related]
9. The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions.
Piccini M; Mannelli F; Coltro G
Bioengineering (Basel); 2023 May; 10(5):. PubMed ID: 37237661
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting.
Gong X; Zhang Y; He X; Moloudizargari M; Yu T; Wang L; Liu W; Jin L; Xu H; Xu Y; Tao Z; Qian W
Exp Hematol Oncol; 2023 Jun; 12(1):57. PubMed ID: 37391809
[TBL] [Abstract][Full Text] [Related]
11. Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia.
Wang J; Tomlinson B; Lazarus HM
Curr Treat Options Oncol; 2023 Jul; 24(7):770-801. PubMed ID: 37195589
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.
Wang C; Zhao K; Hu S; Dong W; Gong Y; Xie C
Oncologist; 2023 Jun; 28(6):e397-e405. PubMed ID: 37116899
[TBL] [Abstract][Full Text] [Related]
13. Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma.
Li X; Ding X; Liu M; Wang J; Li W; Chen J
Oncologist; 2023 Oct; 28(10):e942-e949. PubMed ID: 37105140
[TBL] [Abstract][Full Text] [Related]
14. Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study.
Zhao L; Fu Y; Niu P; Zhang F; Jiao F; Zhou X; Wu Z; Wang W; Luan X; Han X; He M; Guan Q; Li Y; Zhao D; Gao J; Chen Y
Oncologist; 2023 Oct; 28(10):e891-e901. PubMed ID: 37104872
[TBL] [Abstract][Full Text] [Related]
15. The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms.
Liu M; Li N; Tang H; Chen L; Liu X; Wang Y; Lin Y; Luo Y; Wei S; Wen W; Chen M; Wang J; Zhang N; Chen J
Oncologist; 2023 Sep; 28(9):e723-e736. PubMed ID: 37086484
[TBL] [Abstract][Full Text] [Related]
16. Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy.
Cheng X; Chen B; Wang S; Zhang J; Zhu J; Liu M; Liu S; Xi M
Oncologist; 2023 Aug; 28(8):e606-e616. PubMed ID: 37061835
[TBL] [Abstract][Full Text] [Related]
17. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
Dillon LW; Gui G; Page KM; Ravindra N; Wong ZC; Andrew G; Mukherjee D; Zeger SL; El Chaer F; Spellman S; Howard A; Chen K; Auletta J; Devine SM; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Weisdorf DJ; Hourigan CS
JAMA; 2023 Mar; 329(9):745-755. PubMed ID: 36881031
[TBL] [Abstract][Full Text] [Related]
18. Gene Mutations and Targeted Therapies of Myeloid Sarcoma.
Fu L; Zhang Z; Chen Z; Fu J; Hong P; Feng W
Curr Treat Options Oncol; 2023 Apr; 24(4):338-352. PubMed ID: 36877373
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
